Clinical practice guidelines for duodenal cancer 2025
Satoshi Yasuda, Kenji Nakagawa, Mitsuhiro Fujishiro, Naomi Kakushima et autres
jp (code pays fourni par la source)
0 citations
Journal of Gastroenterology
Yukiya Narita
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
202Publications signalées
2075Citations signalées
1Affiliations récentes
Les institutions déclarées
Les domaines associés
Gastric Cancer Management and OutcomesColorectal Cancer Treatments and StudiesCancer Immunotherapy and BiomarkersGastrointestinal Tumor Research and TreatmentEsophageal Cancer Research and Treatment
Les publications récentes
Response to nivolumab as an immune checkpoint inhibitor rechallenge for esophageal squamous cell carcinoma with PD-L1 amplification: a case report
Hiroyuki Kodama, Toshiki Masuishi, Yasunobu Ishizuka, Tomoki Sakakida et autres
jp (code pays fourni par la source)
0 citations
Therapeutic Advances in Medical Oncology
Table S1 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
Chie Kudo-Saito, Hirokazu Shoji, Kengo Nagashima, H. Imazeki et autres
0 citations
Clinical Impact of Trastuzumab Deruxtecan in Patients With HER2-Positive Advanced Gastric Cancer and Ascites: Findings From the EN-DEAVOR Study
Keiko Minashi, Rin Inamoto, Hisato Kawakami, Koki Nakanishi et autres
jp (code pays fourni par la source)
0 citations
Journal of the Korean Gastric Cancer Association
The FSTL1-DIP2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer
Chie Kudo‐Saito, Hiroshi Imazeki, Kengo Nagashima, Hirokazu Shoji et autres
jp, gb (code pays fourni par la source)
1 citation
Cancer Immunology Immunotherapy
Peripheral SNCA+ cells as a poor prognostic factor for nivolumab therapy in advanced gastric cancer
Chie Kudo‐Saito, Hiroshi Imazeki, Kengo Nagashima, Hirokazu Shoji et autres
jp, gb (code pays fourni par la source)
1 citation
Discover Oncology
IL33-ST2 axis is a predictive biomarker for anti-PD1 therapeutic efficacy in advanced gastric cancer
Chie Kudo‐Saito, Hiroshi Imazeki, Kengo Nagashima, Hirokazu Shoji et autres
jp, gb (code pays fourni par la source)
0 citations
Journal of Translational Medicine
Supplementary Table S2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Kohei Shitara, Motohiro Tamiya, Kyoichi Okishio, Hisashi Hosaka et autres
0 citations
Supplementary Table S3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Kohei Shitara, Motohiro Tamiya, Kyoichi Okishio, Hisashi Hosaka et autres
0 citations
Supplementary Table S1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Kohei Shitara, Motohiro Tamiya, Kyoichi Okishio, Hisashi Hosaka et autres
0 citations
Supplementary Table S1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Kohei Shitara, Motohiro Tamiya, Kyoichi Okishio, Hisashi Hosaka et autres
0 citations
Supplementary Table S2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Kohei Shitara, Motohiro Tamiya, Kyoichi Okishio, Hisashi Hosaka et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.